Lu Chaoxia, Wu Wei, Xiao Jifang, Meng Yan, Zhang Shuyang, Zhang Xue
McKusick-Zhang Center for Genetic Medicine, Institute of Basic Medical Sciences, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013 Jun;30(3):301-4. doi: 10.3760/cma.j.issn.1003-9406.2013.03.011.
To detect pathogenic mutations in Marfan syndrome (MFS) using an Ion Torrent Personal Genome Machine (PGM) and to validate the result of targeted next-generation semiconductor sequencing for the diagnosis of genetic disorders.
Peripheral blood samples were collected from three MFS patients and a normal control with informed consent. Genomic DNA was isolated by standard method and then subjected to targeted sequencing using an Ion Ampliseq(TM) Inherited Disease Panel. Three multiplex PCR reactions were carried out to amplify the coding exons of 328 genes including FBN1, TGFBR1 and TGFBR2. DNA fragments from different samples were ligated with barcoded sequencing adaptors. Template preparation and emulsion PCR, and Ion Sphere Particles enrichment were carried out using an Ion One Touch system. The ion sphere particles were sequenced on a 318 chip using the PGM platform. Data from the PGM runs were processed using an Ion Torrent Suite 3.2 software to generate sequence reads. After sequence alignment and extraction of SNPs and indels, all the variants were filtered against dbSNP137. DNA sequences were visualized with an Integrated Genomics Viewer. The most likely disease-causing variants were analyzed by Sanger sequencing.
The PGM sequencing has yielded an output of 855.80 Mb, with a > 100 × median sequencing depth and a coverage of > 98% for the targeted regions in all the four samples. After data analysis and database filtering, one known missense mutation (p.E1811K) and two novel premature termination mutations (p.E2264X and p.L871FfsX23) in the FBN1 gene were identified in the three MFS patients. All mutations were verified by conventional Sanger sequencing.
Pathogenic FBN1 mutations have been identified in all patients with MFS, indicating that the targeted next-generation sequencing on the PGM sequencers can be applied for accurate and high-throughput testing of genetic disorders.
使用Ion Torrent个人基因组测序仪(PGM)检测马凡综合征(MFS)的致病突变,并验证靶向新一代半导体测序用于遗传疾病诊断的结果。
在获得知情同意后,采集了3例马凡综合征患者和1例正常对照的外周血样本。采用标准方法分离基因组DNA,然后使用Ion Ampliseq™遗传疾病检测板进行靶向测序。进行三轮多重PCR反应,以扩增包括FBN1、TGFBR1和TGFBR2在内的328个基因的编码外显子。将不同样本的DNA片段与带条形码的测序接头连接。使用Ion One Touch系统进行模板制备、乳液PCR和离子球颗粒富集。使用PGM平台在318芯片上对离子球颗粒进行测序。使用Ion Torrent Suite 3.2软件处理PGM运行的数据以生成序列读数。在进行序列比对并提取单核苷酸多态性(SNP)和插入缺失(indel)后,所有变异均与dbSNP137进行比对筛选。使用综合基因组浏览器(Integrated Genomics Viewer)查看DNA序列。通过桑格测序法分析最可能的致病变异。
PGM测序产生了855.80 Mb的输出数据,所有4个样本中靶向区域的中位数测序深度>100×,覆盖率>98%。经过数据分析和数据库筛选,在3例马凡综合征患者中鉴定出FBN1基因的1个已知错义突变(p.E1811K)和2个新的过早终止突变(p.E2264X和p.L871FfsX23)。所有突变均通过传统桑格测序法验证。
在所有马凡综合征患者中均鉴定出致病的FBN1突变,表明PGM测序仪上的靶向新一代测序可用于遗传疾病的准确、高通量检测。